Catalyst Wire Dossier Catalyst Wire Dossier

177Lu-girentuximab

girentuximab labeled with Lutetium-177
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for 177Lu-girentuximab, covering 2026-01-14 to 2026-04-16. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC [Phase 1, Phase 2]

See pricing